Examkin

Soru

Zorluk: ZorHematology and Oncology

Match the following clinical scenarios of oncologic therapy and associated toxicities with the most appropriate pharmacological rescue or prophylactic agent.

  • A 42-year-old woman with breast cancer receives a chemotherapy agent known to cause dose-dependent generation of free radicals, leading to cumulative, irreversible dilated cardiomyopathy.Dexrazoxane
  • A 35-year-old man with non-Hodgkin lymphoma receives an alkylating agent that is metabolized in the kidney to acrolein, placing him at high risk for severe hemorrhagic cystitis.Mesna (2-mercaptoethane sulfonate)
  • A 22-year-old man with acute lymphoblastic leukemia receives a high-dose antimetabolite that competitively inhibits dihydrofolate reductase, leading to severe myelosuppression.Leucovorin (Folinic acid)
  • A 15-year-old boy with Burkitt lymphoma is initiating induction chemotherapy for a massive tumor burden, placing him at high risk for acute kidney injury from profound hyperuricemia.Rasburicase

Cevap

The correct matches align each specific chemotherapy-induced toxicity mechanism with its targeted pharmacological rescue or prophylactic agent: Anthracycline cardiotoxicity requires Dexrazoxane; Acrolein-induced cystitis requires Mesna; Methotrexate myelosuppression requires Leucovorin; and hyperuricemia in Tumor Lysis Syndrome is treated with Rasburicase.
Each pair correctly matches a specific oncologic toxicity or complication with its mechanistically appropriate pharmacological intervention. Dexrazoxane chelates iron to prevent anthracycline cardiotoxicity. Mesna binds acrolein to prevent cyclophosphamide-induced cystitis. Leucovorin bypasses DHFR inhibition to rescue normal cells from methotrexate. Rasburicase degrades uric acid to prevent nephropathy in tumor lysis syndrome.

Adım Adım Çözüm

1
Analyze the first scenario to identify the underlying chemotherapy agent and its toxic mechanism.
The agent described is an anthracycline (e.g., doxorubicin), which causes free-radical mediated dilated cardiomyopathy.
Recognizing the pathophysiology is required to select the correct cardioprotectant, which is Dexrazoxane.
2
Identify the cause and prevention of hemorrhagic cystitis in the second scenario.
The alkylating agent (cyclophosphamide) produces acrolein, which is neutralized by Mesna.
Mesna specifically concentrates in the bladder to bind acrolein, preventing urothelial toxicity.
3
Determine the rescue agent for the patient receiving the dihydrofolate reductase inhibitor in the third scenario.
The drug is methotrexate, and its toxicity is mitigated by Leucovorin (folinic acid).
Leucovorin provides the active form of folate, bypassing the blocked enzyme and rescuing rapidly dividing normal cells.
4
Select the most appropriate prophylactic agent for severe hyperuricemia in the fourth scenario.
The high tumor burden puts the patient at risk for tumor lysis syndrome, which is aggressively managed with Rasburicase.
Rasburicase enzymatically degrades uric acid to allantoin, rapidly preventing urate crystal nephropathy in high-risk patients.

Anahtar Kavram

Pharmacological prevention and rescue of specific chemotherapy-induced toxicities and oncologic emergencies.
Tahmini Süre:2m 0s
Bu soruyu puanla

Konular

Hematology and Oncology

Bu konudan daha fazla soru